Abstract：Objective: To evaluate the safety and efficacy of percutaneous MSCT guided interstitial 125I seed implantation treatment for refractory malignant tumor. Methods: Seventy-six lesions(diameter 2.5~12.0cm, mean 6.5cm) in 70 refractory malignant tumor patients underwent percutaneous MSCT guided intratumoral 125I seed implantation. Treatment plan system(TPS) was adopted based on CT imaging 14 days before the procedure. The distribution of 125I seed, complications and efficacy were observed immediately after and 2~8 months after the procedure. Results: The procedure of intratumoral 125I seed implantation in 76 malignant tumors was successful. Ten to ninety particles(mean 45) of 125I seeds were implanted into a single tumor. The distribution of seeds in 71 malignant tumors in 66 patients was satisfactory while the distribution of 125I seeds in 5 malignant tumors of the other 4 cases was not uniform, and the latter 5 malignant tumors of 4 cases were carried out supplementary 125I seed implantation in the tumor cool area 4~8 weeks after the procedure. The clinical CR and PR were achieved in 5 and 45 lesions respectively, with an overall response rate of 65.79％（50/76）. Pneumothorax occurred in 4 cases with lung cancer. No acute complications and treatment related radiation damages occurred in the other cases. Conclusions: The MSCT guided percutaneous intratumoral 125I seed implantation treatment for refractory malignancies is a safe and effective method.
高建华;赵相胜;商健彪. MSCT引导下125Ｉ粒子植入治疗恶性肿瘤的应用价值[J]. , 2008, 19(3): 198-202.
GAO Jian-hua;ZHAO Xiang-sheng;SHANG Jian-biao. Interstitial 125Ｉ seed implantation in the treatment for refractory malignant tumor under the guidance of MSCT. , 2008, 19(3): 198-202.
2008, Vol. 19 
